
News|Articles|October 3, 2026
8 Pulmonology Headlines You Missed in Q3 2026
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Pulmonology has seen significant growth over the past few months, with the acceptance of major New Drug Applications by the
Related to this article

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.

DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.

FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.

Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Advertisement
Advertisement

